The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.
The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.
If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.
News
Currently, cardiovascular disease cause the deaths of some 17 million people each year, which represents nearly one third of all deaths in the world. These figures will probably grow in the years to come, especially in the "developing" world. The incidence of coronary heart disease in these territories will increase due to increased life expectancy and the growing prevalence of features typical of an inadequate life style (smoking, introduction of "fast food", less physical activity, etc).
TRAIN-HEART aims to develop new cutting-edge therapies to cure ischemic heart failure, also known as heart problems caused by narrowed heart arteries.
Tue, 29 September
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813716.
Copyright © 2020
